This year the Nobel Prize in medicine has been rewarded for immunotherapy. Immunotherapy is exciting new way of treating cancer, by activating the patient’s own immune system in the fight against cells. Today, cancer is still one of the deadliest deceases in Denmark with more than 30 % of all deaths. This is why many companies see a big opportunity in immunotherapy. Right now it is the basis of 50 % of all new trials in cancer research. This is also obvious in the Danish biotech sector, with companies like Y-mAbs, IO Biotech og Cytovac.
Read Directing Manager Tove Holm-Larsen’s blog on the subject here (Danish)